Loading…
← CockpitCompetitor Analysis › 002551.SZ Shenzhen Glory Medical Co., Ltd. Class AOpen in the cockpit ↗

Shenzhen Glory Medical Co., Ltd. Class A002551.SZCompetitor analysis, valuation and peers

China · CNY·Industrials›Engineering & Construction
Momentum neutral 57
Mkt cap
$479M
US dollars, full cap
Free float
91%
of shares outstanding
$/day
$6.75M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
-13.3 pp
WACC 8.2%
Hurdle
n/a
no reverse DCF
Close · CNYCN¥2.96
1D-2.0%
1W+1.0%
1M-12.4%
3M-2.0%
6M-17.3%
YTD-18.9%
1Y-28.7%
ATR %4.0%
52w lowhigh29.4% off high

What Shenzhen Glory Medical does

Employees: 1,322

Shenzhen Glory Medical at a glance

Size Shenzhen Glory Medical (002551.SZ) is a China Industrials company (Engineering & Construction) with a market value of $479M, the 3950th largest of 4,839 China companies the cockpit tracks. Shares closed at CN¥2.96 on 6 Nov 2026.

Performance Over six months the shares fell 17.3%, against -17.4% for the median peer and -16.4% for the China market (cap-weighted) — 11th highest of 21 in its peer set.

Growth Revenue fell 3.3% over the last twelve months (peer median -0.9%); the operating margin is -17.4% (peer median 3.9%).

Valuation It trades at 2.4× enterprise value to sales against a peer median of 1.4× (8th most expensive of 21).

Capital Return on invested capital runs 13.3 points below its cost of capital (8.2% WACC).

Relative performance

809010011 May 202611 Aug 20266 Nov 2026002551.SZ 83Peer median 82
Six months, rebased to 100: Shenzhen Glory Medical against the median of its 20 peers (local-currency closes).

Shenzhen Glory Medical financials

Reported figures in CNY; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueCN¥1.16BCN¥1.07BCN¥1.43BCN¥1.18BCN¥1.26B
Revenue growth—-25%+22%-7%—
Gross profitCN¥167MCN¥84.3MCN¥206MCN¥145MCN¥168M
EBITDAn/a-CN¥78.0MCN¥115M-CN¥13.8M-CN¥68.2M
Net income-CN¥137M-CN¥140MCN¥22.3M-CN¥149M-CN¥308M
Free cash flow-CN¥122MCN¥15.0MCN¥42.5M-CN¥24.4MCN¥39.2M
Capital expenditureCN¥119MCN¥125MCN¥82.1MCN¥42.1MCN¥57.3M
Total debtCN¥147MCN¥126MCN¥344MCN¥367MCN¥390M

Quarterly statements and history in the cockpit →

Shenzhen Glory Medical competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-40%-20%0%-20%-10%0%1882BBCP254319760020371899PRAJIND00262860384300217869036034582530PXMHCC6035593000213007463703002551.SZ6-month return →1-month return →
Up and to the right = strong over both horizons. Shenzhen Glory Medical is the large dot.

Fundamentals: revenue growth against valuation

-20%0%+20%0×5×1882BBCP254319760020371899PRAJIND00262860384300217869036034582530PXMHCC6035593000216005123007463703002551.SZRevenue growth (TTM) →EV / Sales →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Shenzhen Glory Medical is the large dot.

Shenzhen Glory Medical competitors and peer comparison

How Shenzhen Glory Medical compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Shenzhen Glory Medical against its 20 peers (data as of 6 Nov 2026)
Measure002551.SZPeer medianRank in peer set
1-month return-12.4%-8.6%7th lowest of 21
6-month return-17.3%-17.4%11th highest of 21
Distance from 52-week high-29.4%-36.1%7th highest of 21
Revenue growth (TTM)-3.3%-0.9%10th lowest of 21
Operating margin-17.4%3.9%5th lowest of 21
EV / Sales2.4×1.4×8th most expensive of 21
ROIC minus cost of capital-13.3 pp-2.5 pp4th lowest of 21

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
Shenzhen Glory Medical 002551.SZChina$479M-17%-3%-17%2.4×n/an/a
TOA ROAD 1882.TJapan$479M-4%-4%5%0.5×-8.4%+1.6%
Concrete Pumping BBCPUnited States$479M+20%+7%12%2.1×9.9%+5.2%
Hwang Chang General Contractor 2543.TWTaiwan$480M-32%+31%14%1.4×n/an/a
Meisei Industrial 1976.TJapan$478M-12%-5%13%0.7×-9.6%+3.6%
Poly Union Chemical 002037.SZChina$477M-23%-11%-8%1.4×n/an/a
Fukuda 1899.TJapan$483M+10%+6%6%0.2×-19.9%-2.0%
PRAJ Industries PRAJIND.NSIndia$486M-38%+2%2%1.3×49.1%+19.4%
Chengdu Road & Bridge Engineering 002628.SZChina$472M-24%+1%-23%5.3×24.8%-16.2%
Zhengping Road & Bridge Construction 603843.SSChina$469M-50%-15%-18%4.8×n/an/a
Shanghai Yanhua Smartech 002178.SZChina$492M-21%-22%-5%9.1×n/an/a
Jiu Han System Technology 6903.TWOTaiwan$494M-40%+196%27%2.1×-3.0%+11.0%
Guizhou Transportation Planning Survey & Design Academe 603458.SSChina$462M-14%-19%-35%2.6×-0.4%-13.7%
Delpha Construction 2530.TWTaiwan$462M-11%-59%26%10.2×n/an/a
Polimex - Mostostal PXM.WAPoland$462M-14%+21%4%0.3×2.2%+20.7%
Hindustan Construction HCC.NSIndia$500M-26%-21%12%1.2×n/an/a
Zhongtongguomai Communication 603559.SSChina$455M-1%+1%-18%6.7×n/an/a
Dayu Irrigation 300021.SZChina$506M-26%-15%4%1.4×n/an/a
Tengda Construction 600512.SSChina$452M-21%+32%-3%0.2×n/an/a
Hanjia Digital Intelligence Science and Technology 300746.SZChina$452M+7%-2%0%3.4×47.6%-10.5%
Continental 3703.TWTaiwan$509M0%+7%6%1.4×0.0%+9.7%

Questions

Which companies are Shenzhen Glory Medical's closest peers?
The cockpit's peer set: TOA ROAD (1882.T), Concrete Pumping (BBCP), Hwang Chang General Contractor (2543.TW), Meisei Industrial (1976.T), Poly Union Chemical (002037.SZ), Fukuda (1899.T), PRAJ Industries (PRAJIND.NS), Chengdu Road & Bridge Engineering (002628.SZ).
Is Shenzhen Glory Medical expensive compared with its peers?
On ev / sales it trades at 2.4× against a peer median of 1.4×, 8th most expensive of 21 in its peer set.
How has Shenzhen Glory Medical stock performed?
Over six months to 6 Nov 2026 the shares returned -17.3% against -17.4% for the median peer; over one year -28.7%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.